<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601883</url>
  </required_header>
  <id_info>
    <org_study_id>APPI2-2020-AD03</org_study_id>
    <nct_id>NCT04601883</nct_id>
  </id_info>
  <brief_title>Colchicine as Treatment for People With Hand Osteoarthritis</brief_title>
  <acronym>COLOR</acronym>
  <official_title>Colchicine Treatment for Patients With Hand Osteoarthritis: A Randomised, Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henning Bliddal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frederiksberg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare oral colchicine 0.5 mg administered two times daily for 12 weeks&#xD;
      with placebo as a treatment of hand OA symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Finger pain</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, on changes in finger joint pain of the target hand from baseline to week 12, in patients with painful hand OA measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in function of both hands measured on the Australian/Canadian Hand Index Function Score spanning from 0 to 900, where higher scores equals worse function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thumb base pain</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in thumb base pain of the target hand measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain hands</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in pain of both hands measured on the Australian/Canadian Hand Index Pain Score spanning from 0 to 500, where higher scores equals worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint activity</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in joint activity of the target hand measured on physician tender joint count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in patient global assessment measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by European Quality of Life 5 Dimensions</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in quality of life measured on the European Quality of Life 5 Dimensions spanning from -0.624 to 1.000, where higher scores equals better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand strength</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in hand strength of the target hand measured on grippit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment responders according to OMERACT-OARSI response criteria</measure>
    <time_frame>Week 12</time_frame>
    <description>The following two conditions is observed at the post-baseline assessment:&#xD;
In either pain (finger pain) or function (function), a high improvement in the subscale, where high improvement in a subscale is achieved if there is both a &gt; 50% improvement from Baseline and an absolute change from Baseline of &gt; 20 percent points (0-100 scale), OR&#xD;
Improvement in at least two of the following three:&#xD;
Improvement in pain (finger pain) defined as &gt; 20% improvement from Baseline and an absolute change from Baseline of &gt; 10 points (0-100 scale)&#xD;
Improvement in function (function) defined as &gt; 20% improvement from Baseline and an absolute change from Baseline of &gt; 10 points (0-100 scale)&#xD;
Improvement in patient's global assessment defined as &gt; 20% improvement from Baseline and an absolute change from Baseline of &gt; 10 mm (0-100 scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis Hand</condition>
  <condition>Osteoarthritis Finger</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet colchicine 0.5 mg administered two times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet placebo administered two times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 0.5 MG</intervention_name>
    <description>The intervention tablets are commercially available Colchicine &quot;Tiofarma&quot;</description>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Encapsulated placebo tablets. Placebo is identical to the active intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Hand OA according to the ACR criteria above.&#xD;
&#xD;
          3. Hand OA finger pain: Pain at rest ≥40 mm on VAS (0 to 100 mm range).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Comorbidities&#xD;
&#xD;
          1. Other known medical disease that may affect joints, e.g. RA, gout, PsA&#xD;
&#xD;
          2. Positive anti-cyclic citrullinated peptide (&gt;10 kU/L)&#xD;
&#xD;
          3. Known cutaneous deposition diseases (e.g. amyloidosis or porphyria).&#xD;
&#xD;
          4. Known blood dyscrasias and coagulation disorders&#xD;
&#xD;
          5. Known malignancy (except successfully treated squamous or basal cell skin carcinoma)&#xD;
&#xD;
          6. Elevated alanine transaminase (&gt;45 U/L females, &gt;70 U/L for males)&#xD;
&#xD;
          7. Creatinine clearance ≤60 ml/min&#xD;
&#xD;
          8. Elevated creatine kinase (&gt;210 U/L females, &gt;280 U/L for males)&#xD;
&#xD;
          9. Known allergies towards the interventions&#xD;
&#xD;
         10. Drug or alcohol abuse in the last year&#xD;
&#xD;
         11. Generalised pain syndromes such as fibromyalgia&#xD;
&#xD;
         12. Current reflux&#xD;
&#xD;
         13. Current or recurrent diarrhoeal illnesses&#xD;
&#xD;
         14. Current abdominal pain&#xD;
&#xD;
         15. Known peripheral neuropathies&#xD;
&#xD;
         16. Any other condition or impairment that, in the opinion of the investigator, makes a&#xD;
             potential participant unsuitable for participation or which obstruct participation,&#xD;
             such as e.g. psychiatric disorders.&#xD;
&#xD;
             Medical history&#xD;
&#xD;
         17. History of hand surgery within 12 months prior enrolment.&#xD;
&#xD;
         18. History of arthroplasty or arthrodesis in the hand Management strategies&#xD;
&#xD;
         19. Treatment with P-glycoprotein inhibitors and/or cytochrome P450 3A4 (CYP3A4)&#xD;
             inhibitors, see section &quot;Colchicine safety in drug-drug interactions&quot; and table 7. If&#xD;
             potential participants have been treated with these pharmaceuticals previously,&#xD;
             treatment must be terminated 5 half-lifes before initiation of study drug.&#xD;
&#xD;
         20. Use of systemic corticosteroids equivalent of ≥ 7.5 mg prednisolone daily within 3&#xD;
             months.&#xD;
&#xD;
         21. Participation in experimental device or experimental drug study 3 months prior to&#xD;
             enrolment.&#xD;
&#xD;
         22. Intra-articular treatments or aspirations of any kind of any joint in the hands 3&#xD;
             months before inclusion&#xD;
&#xD;
         23. Intra-articular corticosteroids into any joint 1 months before inclusion&#xD;
&#xD;
         24. Current use of synthetic or non-synthetic opioids&#xD;
&#xD;
         25. Scheduled surgery during study participation&#xD;
&#xD;
         26. Planning to start other treatment for hand OA in the study participation period.&#xD;
&#xD;
             Reproductive system&#xD;
&#xD;
         27. Pregnancy.&#xD;
&#xD;
         28. Planned pregnancy within the study period, 3 months after end of study treatment for&#xD;
             female fertile participant and 6 months after end of study treatment for male&#xD;
             participant.&#xD;
&#xD;
         29. Insufficient anti-conception therapy for female fertile participants within the study&#xD;
             period and 3 months after end of study treatment. Sufficient anti-conception therapy&#xD;
             consists of intra-uterine device (coil),hormonal anti-conception (birth control pills,&#xD;
             implant, intra-uterine system, dermal patch, vaginal ring, or injections) or sexual&#xD;
             abstinence Female participants are considered infertile if they are postmenopausal or&#xD;
             if they have undergone surgical sterilisation (bilateral salpingectomy, hysterectomy&#xD;
             or bilateral oophorectomy). Postmenopausal state is defined as no menses for 12 months&#xD;
             without alternative medical cause before inclusion in the study. Menopause state will&#xD;
             be confirmed by measurement of follicle stimulating hormone.&#xD;
&#xD;
         30. Insufficient anti-conception therapy for male participants within the study period and&#xD;
             6 months after end of study treatment. Sufficient anti-conception therapy consists of&#xD;
             condom or sexual abstinence. Male participants are considered sterile if they have&#xD;
             undergone surgical sterilisation (vasectomy).&#xD;
&#xD;
         31. Breast-feeding&#xD;
&#xD;
        A target hand will be selected for outcome assessment once individual fulfills in- and&#xD;
        exclusions criterias. Selection of the target hand will adhere to the following, with&#xD;
        advancement to next step if unable to choose target hand based on the given criteria.&#xD;
&#xD;
          1. The hand with most overall pain, assessed by VAS finger joint pain.&#xD;
&#xD;
          2. The hand with most overall reduced function, assessed by AUSCAN function subscale.&#xD;
&#xD;
          3. The hand with most overall stiffness, assessed by AUSCAN stiffness subscale.&#xD;
&#xD;
          4. The hand with most swollen joints, assessed by physician joint count.&#xD;
&#xD;
          5. The hand with most tender joints, assessed by physician joint count.&#xD;
&#xD;
          6. The hand with highest summed radiographic score, assessed by radiographic scoring of&#xD;
             conventional X-ray.&#xD;
&#xD;
          7. If unable to select target hand based on the above criteria, a target hand will be&#xD;
             randomly assigned.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Døssing, MD</last_name>
    <phone>+4538164153</phone>
    <email>anna.dossing@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marius Henriksen, Pt, PhD</last_name>
    <phone>+4538164160</phone>
    <email>marius.henriksen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Parker Institute, Bispebjerg and Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>DK</state>
        <zip>2500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Døssing, MD</last_name>
      <phone>+4538164153</phone>
      <email>anna.dossing@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marius Henriksen, Pt, PhD</last_name>
      <phone>+4538164160</phone>
      <email>marius.henriksen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Henning Bliddal, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Frederiksberg University Hospital</investigator_affiliation>
    <investigator_full_name>Henning Bliddal</investigator_full_name>
    <investigator_title>MD, DMSci, Professor of Rheumatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

